Pulmozyme Market Report 2026

Pulmozyme Market Overview

• The Pulmozyme market growth in the historic period has been driven by established efficacy in aat deficiency, pulmonology guideline support • Market expansion is supported by increasing genetic screening programs, rising copd burden • Growth Driver: Rising Respiratory Disorders Fuel Pulmozyme Demand • Market Trend: FDA Approval Of Pulmogine Vibrating Mesh Nebulizer Enhances Pulmozyme Delivery And Patient Compliance • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Pulmozyme Market?

Pulmozyme (Dornase alfa) is a recombinant human deoxyribonuclease I (DNase I) enzyme used primarily in the treatment of cystic fibrosis (CF). It works by breaking down DNA in the thick mucus secretions present in the lungs of patients, reducing mucus viscosity and improving lung function. Delivered via a nebulizer, Pulmozyme improves lung function, facilitates easier breathing, and lowers the risk of respiratory infections. The main indications for pulmozyme are cystic fibrosis, and respiratory tract infections. A genetic disorder causes thick, sticky mucus to accumulate in the lungs and digestive system, leading to breathing difficulties and recurring lung infections. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies and are used by various end-users such as hospitals and clinics, and homecare settings.

What Is The Pulmozyme Market Growth Forecast?

The growth in the forecast period can be attributed to increasing genetic screening programs, rising copd burden, expansion of specialty respiratory care, improved patient adherence, growth of plasma collection infrastructure. Major trends in the forecast period include rising adoption of augmentation therapy, focus on preventing copd progression, long term plasma protein replacement use, hospital and specialty clinic administration, growth in genetic lung disorder awareness.

Global Pulmozyme Market Segmentation

1) By Indication: Cystic Fibrosis, Respiratory Tract Infections 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By End User: Hospitals And Clinics, Homecare Settings

What Are The Drivers Of The Pulmozyme Market?

The rise in respiratory disorders is expected to propel the growth of the pulmozyne market going forward. Respiratory disorders are medical conditions affecting the lungs and airways, impairing breathing and oxygen exchange, including diseases such as asthma, COPD, and pneumonia. The rise in respiratory disorders is driven by increasing air pollution, smoking, occupational hazards, climate change, and higher prevalence of allergens and infectious diseases. Pulmozyme (dornase alfa) is used to manage respiratory disorders such as cystic fibrosis by breaking down thick mucus in the lungs, improving airflow and reducing infection risk. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, approximately 8.5 million people in Australia, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people, or 11% of the population, living with asthma, and 638,000 people, or 2.5% of the population, living with chronic obstructive pulmonary disease (COPD). Therefore, the rise in respiratory disorders drives the pulmozyme industry. The rise in the number of lung transplants is expected to propel the growth of the pulmozyme market going forward. A lung transplant is a surgical procedure in which a diseased or failing lung is replaced with a healthy donor lung to treat severe respiratory failure or chronic lung diseases. The rise in number of lung transplants is due to an increase in the prevalence of chronic respiratory diseases such as cystic fibrosis and COPD, improved surgical techniques, and advancements in post-transplant care that enhance survival rates. Pulmozyme, a recombinant human DNase enzyme, helps lung transplant patients by breaking down the thick, sticky mucus in their airways, reducing the risk of infections and improving lung function, which ultimately aids in enhancing their ability to breathe and maintain respiratory health post-transplant. For instance, in August 2023, the National Health Service (NHS), a UK-based healthcare system, the total number of UK citizens with active lung and heart-lung transplants in 2022 accounted for 267, which increased to 302 in 2023. Therefore, the increase in the number of lung transplants drives the pulmozyme industry.

Key Players In The Global Pulmozyme Market

Major companies operating in the pulmozyme market are Roche Holding AG

Global Pulmozyme Market Trends and Insights

Major companies operating in the cystic fibrosis treatment device market are focusing on developing advanced solutions, such as vibrating mesh nebulizers, to enhance drug delivery, improve treatment adherence, and elevate patient quality of life. Vibrating mesh nebulizers refer to devices that use a fine mesh to generate a consistent aerosol, enabling more efficient and targeted delivery of medications like Pulmozyme to the lungs. For instance, in March 2024, HCmed, a Taiwan-based medical technology company, announced that its Pulmogine Vibrating Mesh Nebulizer received FDA approval for use with Pulmozyme, making it one of only five FDA-approved mesh nebulizer devices compatible with this therapy. This approval underscores the market’s focus on innovative delivery devices that optimize therapy outcomes and patient experience.

Regional Insights

North America was the largest region in the pulmozyme market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pulmozyme Market?

The pulmozyme market consists of sales of inhalation solutions, nebulizer solutions, and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmozyme Market Report 2026?

The pulmozyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmozyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.